The developing promise for aplnergic therapeutics in cardiac and renal diseases suggests another, supplemental role for APLN and ELA, as candidate biomarkers of a multisystem axis that counteract the effects of RAAS (1, 6, 10). This evidence concerns the gene APLN and kidney disorder.